Recent share performance and business profile

Denali Therapeutics (DNLI) has been on many watchlists after a mixed stretch in the share price, with a loss of about 10% over the past month but a gain of roughly 13% over the past 3 months.

At a last close of US$19.29 and a market value of about US$3.1b, Denali Therapeutics develops treatments targeting neurodegenerative and lysosomal storage diseases, including programs for Parkinson’s disease, frontotemporal dementia, Hunter Syndrome, and certain forms of mucopolysaccharidosis.

Recent trading shows momentum cooling in the short term, with a 7 day share price return of 6.6% and a 30 day share price return of 10%. This contrasts with the 1 year total shareholder return of 54.3% and the weaker 3 and 5 year total shareholder returns of 22% and 65.6% respectively.

If Denali’s recent moves in biotech have your attention, it can be helpful to broaden your watchlist to other healthcare names using our screener of 36 healthcare AI stocks

With Denali reporting strong annual revenue and net income growth, alongside a recent share pullback and a price that sits well below analyst targets, you have to ask: is this a fresh entry point, or is the market already factoring in future growth?

Preferred price to book multiple of 3x: Is it justified?

On a P/B of about 3x at a last close of $19.29, Denali trades above the wider US biotechs average of roughly 2.3x but well below a peer group average closer to 23x.

The P/B ratio compares the share price to the company’s net assets per share, so it is often used for early stage biopharma where earnings are still negative. For Denali, this means investors are paying a multiple of the company’s book value despite it reporting a net loss of $512.54m and having immaterial reported revenue.

Relative to the broader US biotechs industry, the 3x P/B suggests the market is assigning a richer valuation than the sector average. This may reflect expectations around the company’s neurodegenerative and lysosomal storage disease pipeline and the 50.1% forecast annual revenue growth. At the same time, sitting far below the peer group average multiple highlights how widely valuations can differ across comparable names and shows that Denali is priced at a premium to the sector but at a discount to that smaller peer set.

Result: Price to book ratio of 3x (ABOUT RIGHT)

However, you also have to weigh clinical setbacks or partnership changes, along with the current annual net loss of US$512.54m and immaterial revenue, as potential pressure points.

Next Steps

With a mix of potential upsides and clear risks in play, this is a moment to move quickly beyond headlines and review the details yourself. You can start with the 2 key rewards and 2 important warning signs.

Looking for more investment ideas?

If Denali is already on your radar, do not stop there. Broaden your opportunity set by scanning other focused lists of stocks that match your style.

• Target potential bargains by reviewing our list of companies screened as 62 high quality undervalued stocks.
• Strengthen your income stream by checking stocks highlighted as 11 dividend fortresses.
• Prioritize capital protection by focusing on companies filtered as 73 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.